Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use

Pediatric Blood and Cancer

Volumn 63, Issue 12, 2016, Pages 2146-2153

  Green, Nancy S ^a   Manwani, Deepa ^b   Qureshi, Mahvish ^a   Ireland, Karen ^b   Sinha, Arpan ^b   Smaldone, Arlene M ^a  

^a Department of Medicine   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

fetal hemoglobin; hydroxyurea; medication adherence; sickle cell disease

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; ANTISICKLING AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; DISEASE CONTROL; FEMALE; FIRST AID; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SICKLE CELL ANEMIA; TREATMENT DURATION; ANEMIA, SICKLE CELL; BLOOD; HOSPITAL EMERGENCY SERVICE; LENGTH OF STAY;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; EMERGENCY SERVICE, HOSPITAL; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; LENGTH OF STAY; MALE; RETROSPECTIVE STUDIES;

EID: 84992029060     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26161     Document Type: Article

References (42)

1. Ware RE, Despotovic JM, Mortier NA, et al., Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–4991.
2. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3):158–165.
3. Zimmerman SA, Schultz, WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–2045.
4. Kinney TR, Helms RW, O'Branksi EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550–1554.
5. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood. 2005;106(7):2269–2275.
6. Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):436–443.
7. Hankins JS, Aygun B, Nottage K, et al. From infancy to adolescence: Fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore). 2014;93(28):e215.
8. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628–3632.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
10. McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: A systematic review. Pediatrics. 2013;132(4):730–740.
11. Borus JS, Laffel L. Adherence challenges in the management of type 1 diabetes in adolescents: Prevention and intervention. Curr Opin Pediatr. 2010;22(4):405–411.
12. Desai M, Oppenheimer JJ. Medication adherence in the asthmatic child and adolescent. Curr Allergy Asthma Rep. 2011;11(6):454–464.
13. Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health. 2008;13(1):19–24.
14. Salema NE, Elliott RA, Glazebrook C. A systematic review of adherence-enhancing interventions in adolescents taking long-term medicines. J Adolesc Health. 2011;49(5):455–466.
15. Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142–151.
16. Anderson BJ. Who forgot? The challenges of family responsibility for adherence in vulnerable pediatric populations. Pediatrics. 2012;129(5):e1324–1325.
17. Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273–277.
18. Ritho J, Liu H, Hartzema AG, Lottenberg R. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Am J Hematol. 2011;86(10):888–890.
19. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415–419.
20. Walsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: A systematic review. Pediatrics. 2014;134(6):1175–1183.
21. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50(5):619–625.
22. Patel NG, Lindsey T, Strunk RC, DeBaun MR. Prevalence of daily medication adherence among children with sickle cell disease: A 1-year retrospective cohort analysis. Pediatr Blood Cancer. 2010;55(3):554–556.
23. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013;27(3):329–340.
24. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–574; discussion 575–577.
25. Nevin J, Myers L, Osunkwo I, Kanter J. A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea. J Pediatr Hematol Oncol. 2014;36(3):e180–e184.
26. Green NS, Ender KL, Pashankar F, et al. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. PLoS ONE. 2013;8(2):e55709.
27. Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2014;75(1–2):196–204.
28. Helgeson VS, Reynolds KA, Siminerio L, Escobar O, Becker D. Parent and adolescent distribution of responsibility for diabetes self-care: Links to health outcomes. J Pediatr Psychol. 2008;33(5):497–508.
29. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010;24(1):199–214.
30. Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: The what, why, when and how. BMC Med Res Methodol. 2013;13:92.
31. Naranjo D, Mulvaney S, McGrath M, Garnero T, Hood K. Predictors of self-management in pediatric type 1 diabetes: Individual, family, systemic, and technologic influences. Curr Diab Rep. 2014;14(11):544.
32. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–1369.
33. Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction: What doesn't kill red blood cells may make them stronger. Exp Hematol. 2008;36(9):1057–1072.
34. Thornburg CD, Rogers ZR, Jeng MR, et al. Adherence to study medication and visits: Data from the BABY HUG trial. Pediatr Blood Cancer. 2010;54(2):260–264.
35. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: The battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3(3):255–260.
36. McQuaid EL, Everhart RS, Seifer R, et al. Medication adherence among Latino and non-Latino white children with asthma. Pediatrics. 2012;129(6):e1404–e1410.
37. Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: A Children's Oncology Group study. JAMA Oncol. 2015;1(3):287–295.
38. Bhatia S, Landier W, Hageman L, et al. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: A Children's Oncology Group study. Blood. 2014;124(15):2345–2353.
39. Oyeku SO, Driscoll MC, Cohen HW, et al. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood Cancer. 2013;60(4):653–658.
40. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. Am J Hematol. 2010;85(8):611–613.
41. Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatr Blood Cancer. 2014;61(11):2031–2036.
42. Creary SE, Gladwin MT, Byrne M, Hildesheim M, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease. Pediatr Blood Cancer. 2014;61(6):1068–1073.